The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Once-weekly cagrilintide–semaglutide combination therapy produced unprecedented weight reductions in adults with overweight or obesity, with 60% achieving ≥20% loss and strong cardiometabolic benefits ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and help overcome both diabetes and obesity, a new clinical trial suggests.